Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-ac

• Status: Completed
• Trial end date: 2003-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the usefulness of the Risperdal® Consta® Treatment Guidebook in helping the doctor switch the adult patient from taking risperidone tablets daily by mouth to taking long-acting risperidone by injection. The study will also evaluate the effectiveness and safety of long-acting risperidone and its effect on patient satisfaction.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• Collaborator: Janssen, LP
• Treatments: Risperidone

Criteria

Inclusion Criteria:

• Diagnosis of schizophrenia or schizoaffective disorder

• stable with respect to disease symptoms and other medical conditions

• taking oral risperidone at doses of 2 to 6 milligrams per day for 4 weeks before start of study

• if female, using birth control.

Exclusion Criteria:

• Hospitalized within past 4 weeks to treat exacerbation of symptoms of schizophrenia

• at risk for injury to self or others

• had electroconvulsive therapy within past year

• presence of liver or kidney impairment

• use of oral antipsychotics (other than risperidone) within past 4 weeks, of injected antipsychotics within past 3 months, of clozapine within past 60 days, or of long-acting risperidone in an earlier study

• pregnant or breast-feeding

• not using birth control

• abusing drugs or alcohol.